The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about many questions as hospitals and blood centers prepare to order the testing. We've put together a FAQ document to clarify what we know today. We will update the document as we get more information on existing questions and as new questions get asked, and will update the blog with the revised FAQ document.
Thanks for your support as we work to rapidly get this testing available to you. You can find the FAQ document here: CTS COVID-19 Questions and Answers
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...